Component

Human carnitine palmitoyltransferase 2 / CPT2

Context-specific entity; species, compartment and exposure are stated on each claim.

3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. Myocytes derived from a CPT2-deficient patient accumulated palmitoylcarnitine; incubation at 38 degrees C accentuated accumulation relative to control myocytes.

    Human carnitine palmitoyltransferase 2 / CPT2 → Human CPT2-deficient myocyte palmitoylcarnitine accumulation source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    machinery_impairment Imported condition classification; unverified.
    evidence_access
    Primary abstract
    experimental_model
    Human patient-derived iPSC myocytes; heat challenge.
    limitations
    A cellular disease model, not a universal plasma threshold or a supplement trial.
    nutrient_topic
    L-Carnitine collection; isomer, preparation, species, exposure and manipulation remain explicit. · L-Carnitine
    plain_language
    A downstream block can leave more loaded carnitine behind.
    primary_references
    Functional analysis of iPSC-derived myocytes from a patient with carnitine palmitoyltransferase II deficiency. · 2014 · https://pubmed.ncbi.nlm.nih.gov/24780397/ · DOI 10.1016/j.bbrc.2014.04.084
    trigger_kind
    machinery_impairment Imported condition classification; unverified.

    L-Carnitine: synthesis, acyl-group transport, fuel selection and nutrient interactions (2026-09-19) · lines 130–136

    AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Human patient-derived iPSC myocytes; heat challenge. · source_derived_draft · unverified_draft

    ## l-carnitine-cpt2-heat A downstream block can leave more loaded carnitine behind. Myocytes derived from a CPT2-deficient patient accumulated palmitoylcarnitine; incubation at 38 degrees C accentuated accumulation relative to control myocytes. Model: Human patient-derived iPSC myocytes; heat challenge. Limitations: A cellular disease model, not a universal plasma threshold or a supplement trial. Evidence access: Primary abstract Functional analysis of iPSC-derived myocytes from a patient with carnitine palmitoyltransferase II deficiency. · 2014 · https://pubmed.ncbi.nlm.nih.gov/24780397/ · DOI 10.1016/j.bbrc.2014.04.084
    Complete structured claim and evidence

  2. Expressed human CPT2 formed medium- and long-chain acylcarnitines from acyl-CoAs; its physiological matrix-side reaction reconverts incoming acylcarnitines to acyl-CoAs plus free carnitine.

    Human carnitine palmitoyltransferase 2 / CPT2 → Palmitoyl-L-carnitine source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary abstract and reviewed UniProt catalytic-reaction record
    experimental_model
    Human CPT2 in yeast homogenates; physiological direction from reviewed UniProt P23786/Rhea 12663.
    limitations
    The experiment directly measured the reverse reaction; direction in a cell depends on compartment and substrates.
    nutrient_topic
    L-Carnitine collection; isomer, preparation, species, exposure and manipulation remain explicit. · L-Carnitine
    plain_language
    The inner enzyme unloads the fatty-acid group and recycles carnitine.
    primary_references
    Carnitine palmitoyltransferase 2: New insights on the substrate specificity and implications for acylcarnitine profiling. · 2010 · https://pubmed.ncbi.nlm.nih.gov/20538056/ · DOI 10.1016/j.bbadis.2010.06.002

    L-Carnitine: synthesis, acyl-group transport, fuel selection and nutrient interactions (2026-09-19) · lines 106–112

    AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Human CPT2 in yeast homogenates; physiological direction from reviewed UniProt P23786/Rhea 12663. · source_derived_draft · unverified_draft

    ## l-carnitine-cpt2-return The inner enzyme unloads the fatty-acid group and recycles carnitine. Expressed human CPT2 formed medium- and long-chain acylcarnitines from acyl-CoAs; its physiological matrix-side reaction reconverts incoming acylcarnitines to acyl-CoAs plus free carnitine. Model: Human CPT2 in yeast homogenates; physiological direction from reviewed UniProt P23786/Rhea 12663. Limitations: The experiment directly measured the reverse reaction; direction in a cell depends on compartment and substrates. Evidence access: Primary abstract and reviewed UniProt catalytic-reaction record Carnitine palmitoyltransferase 2: New insights on the substrate specificity and implications for acylcarnitine profiling. · 2010 · https://pubmed.ncbi.nlm.nih.gov/20538056/ · DOI 10.1016/j.bbadis.2010.06.002
    Complete structured claim and evidence

  3. Human CPT2 had activity with C8-C18 acyl-CoAs but virtually none with short-chain acyl-CoAs or branched-chain amino-acid oxidation intermediates.

    Human carnitine palmitoyltransferase 2 / CPT2 → Propionyl-CoA source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    Recombinant human CPT2 substrate panel.
    limitations
    No claim that every acylcarnitine originates from CPT2.
    nutrient_topic
    L-Carnitine collection; isomer, preparation, species, exposure and manipulation remain explicit. · L-Carnitine
    plain_language
    The long-chain shuttle is not the same enzyme system as short-chain buffering.
    primary_references
    Carnitine palmitoyltransferase 2: New insights on the substrate specificity and implications for acylcarnitine profiling. · 2010 · https://pubmed.ncbi.nlm.nih.gov/20538056/ · DOI 10.1016/j.bbadis.2010.06.002

    L-Carnitine: synthesis, acyl-group transport, fuel selection and nutrient interactions (2026-09-19) · lines 114–120

    AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Recombinant human CPT2 substrate panel. · source_derived_draft · unverified_draft

    ## l-carnitine-cpt2-specificity The long-chain shuttle is not the same enzyme system as short-chain buffering. Human CPT2 had activity with C8-C18 acyl-CoAs but virtually none with short-chain acyl-CoAs or branched-chain amino-acid oxidation intermediates. Model: Recombinant human CPT2 substrate panel. Limitations: No claim that every acylcarnitine originates from CPT2. Evidence access: Primary abstract Carnitine palmitoyltransferase 2: New insights on the substrate specificity and implications for acylcarnitine profiling. · 2010 · https://pubmed.ncbi.nlm.nih.gov/20538056/ · DOI 10.1016/j.bbadis.2010.06.002
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards